Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Quest Diagnostics Launches Molecular Cervical Cancer Test

Published: Thursday, September 06, 2012
Last Updated: Thursday, September 06, 2012
Bookmark and Share
May enhance evaluation of cancer risk in the 1.5 million women who receive an indeterminate Pap test result each year.

Quest Diagnostics announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer. The test is designed to help physicians identify women who are at increased risk of developing malignancy, unless treated, after receiving unclear results for cervical cancer risk from standard screening tests.

"Given that medical guidelines now advise less frequent cervical cancer screening for women, it is more important than ever that testing for this cancer be highly reliable," said Daniel M. Jones, M.D., Ph.D., Medical Director, Cancer Diagnostics Services, Quest Diagnostics. "Testing for abnormalities of the TERC gene is based on the most advanced scientific knowledge available of the molecular changes that turn cervical dysplasia into malignancy. It can potentially act like a 'second opinion' for the thousands of women whose Pap and HPV test results produce an indeterminate picture of cancer risk each year."

The Quest Diagnostics Cervical Cancer TERC test is based on the human telomerase RNA component (TERC) gene marker under a nonexclusive patent license from the National Institutes of Health (NIH).  Research by NIH has shown that the TERC gene is amplified, indicated by an abnormal number of copies of the gene on chromosome arm 3q, in the precursor cells of cervical cancer and therefore may be useful for risk stratification in Papanicolaou (Pap) screening.

"One of NIH's goals is to collaborate with commercial organizations to transform our scientific discoveries into clinically valuable technologies," said Dr. Mark Rohrbaugh, Director of the Office of Technology Transfer at the NIH. "The widespread availability of the TERC test through Quest Diagnostics achieves this goal because it has the potential to improve the prediction of cervical cancer risk for many women. It highlights the potential for successful public-private collaborations to advance the practice of medicine."

In the United States, women are screened for cervical cancer using Pap and/or human papillomavirus (HPV) tests. Neither Pap nor HPV tests provide definitive results for risk for cervical cancer. Pap tests identify and categorize cellular changes according to risk they will become malignant. HPV tests identify infection with HPV, a virus that causes cervical cancer in some women but is cleared by the immune system in others.

The new Quest Diagnostics test is designed as an adjunct to conventional Pap and HPV tests, and is performed on residual samples from Pap tests. It detects abnormal changes to the TERC gene and chromosome 3 to provide a risk assessment of progression to cervical cancer in women who receive indeterminate Pap and/or HPV test results. TERC results help categorize risk in abnormal Pap tests prior to colposcopy, a procedure to visually inspect cellular changes. Women with the highest risk result may benefit from additional cervical biopsies at colposcopy and more aggressive monitoring and treatment, while women with low-risk TERC and HPV results may be less likely to undergo unnecessary follow-up colposcopy and other procedures.

The new test may be particularly helpful in evaluating women whose Pap test shows mild cellular abnormalities known as low-grade squamous intraepithelial lesions (LSIL). Up to 1.5 million women in the United States receive an LSIL result each year. LSIL diagnosis and treatment is associated with higher patient anxiety, morbidity and cost, although many cases never progress to cancer.

Because cervical cancer may not produce symptoms until advanced stages of disease, screening is vital to detect pre-cervical cellular abnormalities. Guidelines issued in 2012 from the American Cancer Society (ACS) recommend that women of normal risk be screened for cervical cancer with a Pap test every three years between ages 21 and 29, and with a Pap and HPV test together every five years between ages 30 and 65. In the past, the ACS and other organizations recommended Pap screening as frequently as every year for normal-risk adult women depending on type of Pap test, age and other factors.

"Cervical cancer used to be a major cause of death in women in the United States, but thanks to screening, physicians can often catch and treat abnormalities before they progress to cancer," said Dr. Jones. "It is important that the medical community continue to promote clinically appropriate testing so we don't backtrack on these gains. With less frequent Pap screening of women, TERC testing is an important tool to ensure women are evaluated reliably and receive the proactive treatment that may prevent malignancy."

Quest Diagnostics is believed to be the first laboratory company with national operations and a full menu of Pap, HPV and biopsy cervical cancer tests to offer a testing service based on the TERC marker, affording physicians and patients with broad access in the United States. The new test builds on the company's growing menu of advanced molecular tests for cervical cancer. In early 2012, the company began to offer testing services to identify E6/E7 messenger RNA to help physicians identify women infected with HPV who may have a significantly increased risk of cervical cancer.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quest Diagnostics to Acquire Laboratory Outreach Service Business
Transaction to extend laboratory partnership serving patients and physicians in Southern California while bolstering Quest's growth strategy in the region.
Wednesday, July 01, 2015
Quest Diagnostics Named "Most Admired Company"
Company earns Fortune Magazine 2015 "World's Most Admired Companies" designation by Fortune Magazine.
Tuesday, February 24, 2015
Quest Diagnostics and CDC Expand Public Health Collaboration
Multi-year fee-based contract for Quest's test data and analytics expertise aims to reveal insights from national testing trends to promote guideline-based care and better outcomes for 4.4 million Americans with viral hepatitis.
Thursday, January 29, 2015
FDA Clears the Focus Diagnostics Simplexa™ Flu A/B & RSV Direct Test
Test kit with eight additional strains is now available directly in the United States.
Wednesday, December 10, 2014
Quest Diagnostics Adds Jeffrey M. Leiden to Board of Directors
Dr. Leiden has more than 20 years of scientific and commercial experience in the pharmaceutical and biotechnology industries.
Saturday, October 25, 2014
Quest Diagnostics Unveils New Clinical Laboratory in Marlborough, Massachusetts
Medical experts from UMass Memorial Medical Group and the University of Massachusetts to provide scientific leadership for testing onsite.
Tuesday, October 07, 2014
More People Testing Positive for Chikungunya Virus in the U.S.
Clinical testing volume and positivity rate both grew after the first case of the infectious disease spread to Western Hemisphere this year.
Friday, September 12, 2014
Quest Diagnostics Adds Vicky Gregg to Board of Directors
Company’s Board of Directors expand the Board to 10 members.
Friday, July 25, 2014
Quest Diagnostics Completes Acquisition of Summit Health
Summit's clients will access Quest's 2,200 patient service centers, biometric analysis.
Wednesday, April 23, 2014
Quest Diagnostics Elects Director
Quest Diagnostics announce that its Board of Directors has elected Timothy L. Main to serve as a director, effective immediately.
Tuesday, January 14, 2014
UC San Francisco and Quest Diagnostics Launch Collaboration
Collaboration to advance the field of precision medicine.
Friday, January 10, 2014
Quest Diagnostics Completes Acquisition of Clinical Outreach Operations of Dignity Health
Acquisition consistent with strategy to drive one to two percent in growth per year through strategically aligned fold-in acquisitions.
Friday, July 05, 2013
Quest Diagnostics Completes Sale of HemoCue Business to Radiometer Medical ApS
Company has completed the sale of its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances.
Wednesday, April 10, 2013
Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services.
Thursday, April 04, 2013
Federal Guidelines Recommend New HIV Testing Method
U.S. Department of Health and Human Services issues medical guidelines recommending genotypic testing to aid HIV therapy selection.
Thursday, March 28, 2013
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos